Pharma Business review is using cookies

ContinueLearn More
Close

News

October 19, 2018

Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC

Daiichi Sankyo has dosed the first patient in a phase 1 trial evaluating its AXL inhibitor DS-1205 in combination with gefitinib in patients with metastatic or unresectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have progressed on therapy with tyrosine kinase inhibitors (TKIs).

Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC